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It is an interesting time for the manage-
ment of emphysema. In this condition,
destruction of lung parenchyma associated
with reduced elastic recoil and dynamic
airways closure produce gas trapping and
increased operating lung volumes, leading
to breathlessness and exercise limitation.
It has historically been deﬁned as an irre-
versible process, which has led to a degree
of therapeutic nihilism. One manifestation
of this has been the curious neglect of
lung volume reduction surgery (LVRS).
Clinical guidelines,1 reﬂecting trial evi-
dence,2 recommend consideration of
LVRS in selected patients with upper lobe
predominant emphysema and poor exer-
cise capacity, the phenotype where
surgery has been shown to produce a sur-
vival beneﬁt. Modern surgical techniques,
unilateral treatment and improved post-
operative care and patient selection mean
that LVRS is also associated with lower
morbidity and mortality than data pub-
lished at the turn of the century had sug-
gested,3 4 with one recent case series
reporting zero 90-day mortality following
unilateral surgery.5
Nevertheless, little effort seems to be
going into identifying this patient popula-
tion and LVRS remains vastly underused
with just 90 procedures taking place in
the UK in 2010–2011. A partial explan-
ation for this may be found in a recent
survey of British Thoracic Society
members that revealed that a signiﬁcant
proportion overestimated the morbidity
and mortality associated with LVRS.6
Only 30% had access to a dedicated
chronic obstructive pulmonary disease
(COPD) multidisciplinary meeting to
review patients, and there was no consen-
sus as to the correct strategy to adopt to
identify appropriate patients.
Over the last decade, bronchoscopic
approaches for lung volume reduction in
emphysema have proliferated. These
include one-way endobronchial valves to
induce lobar collapse,7–10 airway bypass
approaches to create low-resistance extra-
anatomical pathways that allow trapped gas
to escape,11 12 lung volume reduction coils
(LVRC) that re-tension the lung preventing
dynamic airway collapse13 and techniques
intended to reduce lung volumes by scar-
ring either through bronchial thermal
vapour ablation (‘steam’)14 or the use of
biological agents.15 16 These approaches
offer the potential to achieve lung volume
reduction, improving symptoms and even
prolonging survival8 while avoiding the
problems inherent in an invasive surgical
intervention. However, for each approach
issues around the magnitude and duration
of effect, optimum patient selection, safety
proﬁle and cost need to be addressed
through properly conducted clinical trials
with robust endpoints.
Deslee and colleagues present 6-month
and 12-month data from a multicentre,
single-arm study of staged, bilateral
LVRC treatment in patients with severe
emphysema.17 They report improvements
in St George’s Respiratory Questionnaire
(SGRQ) scores of −11.1±13.3 points
12 months following therapy as compared
with baseline, with persistent beneﬁts in
6 minute walking distance (6MWD), forced
expiratory ﬂow in the 1st second (FEV1)
and residual volume (RV) exceeding
accepted minimal clinically important dif-
ferences. These data are encouraging and
add to existing data from short-term con-
trolled trials,13 but the limitations of this
study merit some consideration when con-
sidering the general issues for broncho-
scopic therapies outlined above. It was
uncontrolled and unblinded, with only
roughly half the cohort followed up beyond
6 months and the primary outcome was a
quality of life score. This is questionable in
a single-arm study without a sham proced-
ure, given the powerful placebo effect seen
with this sort of intervention. Nevertheless,
the sustained improvement in lung volumes
seems to indicate a persistent physiological
effect. Longer-term follow-up in rando-
mised controlled studies will be needed to
be able to comment deﬁnitively on sus-
tained beneﬁts of LVRC. The RENEW trial
(clinicaltrials.gov NCT01608490), which is
currently underway with a primary end-
point of 6MWD 12 months post-recruit-
ment will address this.
The authors do not clarify what the dis-
tribution of recruitment among the 11
participating centres was or their prior
experience with the technique. Two
patients recruited for bilateral coil treat-
ment were then thought to be unsuitable
for contralateral treatment on a ‘second
look’ at their imaging. In addition, the
trial was meant to enrol only patients
with heterogeneous disease, yet 13 and 17
of 33 patients reaching 12 months’
follow-up were deemed ‘homogeneous’
on visual and computerised scoring,
respectively. The authors propose that
homogeneous emphysema responds to
treatment with LVRC to a similar extent
to heterogeneous disease, but this must be
considered hypothesis generating only and
to some extent seems to reﬂect a failure in
the application of the initial protocol. The
problem of recruiting patients for lung
volume reduction trials who on post hoc
analysis do not fulﬁl entry criteria is not
unique to this study.7 11
Safety is another key issue. It has been
assumed that bronchoscopic lung volume
reduction is safer and cheaper than LVRS.
Pneumothorax occurred within 30 days in
4 of 155 procedures (3.5%), with a per
patient rate of 11.7% (7/60) during the
follow-up period. Pneumothorax following
bronchoscopic lung volume reduction pro-
cedures can be delayed and can be fatal.
This means that as well as formal safety cri-
teria around lung function and exercise cap-
acity a general clinical assessment of the
patient’s likely ability to cope with this
complication needs to be made. In practice,
relatively few people judged ‘too unwell for
LVRS’ may be eligible for a bronchoscopic
approach. All patients treated as part of this
trial had general anaesthesia in an operating
theatre, but it should be noted that these
procedures can be performed safely in the
bronchoscopy suite under sedation.13
A review article written a decade ago
posed the question ‘Endobronchial lung
volume reduction, a myth, or a marvel?’18
The proliferation of techniques and publica-
tions mean that these approaches can no
longer be considered mythical, but nor any
longer are they ‘a marvel’. Rather, they must
be considered as techniques with a develop-
ing evidence base and varying response rates
and complications where a case must be
made that they represent good value, con-
sidered in terms of the resources employed
and the health outcomes obtained. The
London Respiratory Network has produced
a value pyramid for COPD interventions19
(ﬁgure 1), but it remains to be established
where each bronchoscopic approach will sit.
LVRS was estimated as costing $40,000 per
quality adjusted life year (QALY) based on
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the US National Emphysema Treatment
Trial (NETT),20 but the likely true ﬁgure is
considerably lower, given improvements in
technique with reduced mortality, morbidity
and length of stay.5 21 The cost of LVRCs is
at present high with the list price of the
devices themselves signiﬁcantly exceeding
the national LVRS tariff in the UK.
As with LVRS, the response rates for
bronchoscopic techniques are crucially
dependent on appropriate patient selec-
tion, with different criteria for different
devices. This takes us back to the need to
develop an multi-disciplinary team
(MDT) approach for emphysema5 21
(table 1). Given trial data indicating
improved survival, a failure to offer LVRS
to appropriate patients with COPD and
by extension a failure to make the effort
to identify them seems to us to border on
negligence. The development of a
network of emphysema MDTs should also
facilitate the more rapid delivery of trials
to investigate the efﬁcacy of experimental
treatments and ensure that appropriate
criteria are used to select individuals for
more established interventions such as
endobronchial valves to ensure a high
responder rate and the best value for the
healthcare system.
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Figure 1 The pyramid of value for
COPD interventions developed by the
London Respiratory Network with The
London School of Economics (modiﬁed
from19) gives estimates of cost per
quality adjusted life year gained. LABA
long-acting β2 agonist; QALY, quality
adjusted life year.
Table 1 Approach to selecting patients with emphysema for a possible lung volume reduction procedure
General criteria when considering a lung volume reduction procedure
▸ Significantly reduced exercise capacity.
▸ Lung function impairment with significant hyperinflation.
▸ Sufficiently well to cope with surgery.
▸ Prepared to accept some procedural risk (requires clinicians to be able to communicate this accurately).
▸ There is a ‘window of opportunity’ for intervention. In ‘end-stage’ patients, it may be too late to intervene safely.
Considerations Criteria
▸ Are they too well to consider intervention? ▸ Lung function, exercise capacity, prognosis, Medical Research Council dyspnoea score <3
▸ Are they too unwell for intervention to be safe? ▸ Lung function, frailty, exercise capacity <100 m, oxygen dependence
▸ Is treatment optimal? ▸ Smoking cessation, pulmonary rehabilitation, flu vaccination, inhaled and oral medication
▸ Is their lung function likely to rule out a procedure on safety
grounds?
▸ All three of FEV1, TLco and Kco <20% predicted
▸ Do they have comorbidities that limit likely benefit or
increase risk?
▸ For example, pulmonary hypertension, unstable cardiac disease, malignancy, cerebrovascular disease.
Ongoing smoking (possibility of intervention may help to promote quit attempts)
▸ Have they ever had a CT thorax and if so has it been
reported in terms of emphysema pattern?
▸ Review existing CT’s or obtain a CT if a potential candidate as above
Review CT and lung function in multi-disciplinary teams including respiratory physician, radiologist, thoracic surgeon
Further investigations including echocardiogram, lung perfusion scan and a formal field exercise test (shuttle walk or 6 minute walk test) may be indicated.
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